Showing results (61-70 of 72) with videos related to
Sort By:
Pageof 8
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 10, 2013
Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanomaKerstin Trunzer, Anna C Pavlick, Lynn Schuchter, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 20, 2024
Phase I Study of Fianlimab, a Human Lymphocyte Activation Gene-3 (LAG-3) Monoclonal Antibody, in Combination With Cemiplimab in Advanced MelanomaOmid Hamid, Karl D Lewis, Amy Weise, et al.Journal of the National Comprehensive Cancer Network : JNCCN|June 13, 2018
Merkel Cell Carcinoma, Version 1.2018, NCCN Clinical Practice Guidelines in OncologyChristopher K Bichakjian, Thomas Olencki, Sumaira Z Aasi, et al.Journal of the National Comprehensive Cancer Network : JNCCN|May 11, 2016
Basal Cell Skin Cancer, Version 1.2016, NCCN Clinical Practice Guidelines in OncologyChristopher K Bichakjian, Thomas Olencki, Sumaira Z Aasi, et al.Journal of the National Comprehensive Cancer Network : JNCCN|March 12, 2014
Merkel cell carcinoma, version 1.2014Christopher K Bichakjian, Thomas Olencki, Murad Alam, et al.Cancer Discovery|November 12, 2021
Adjuvant Pembrolizumab versus IFNα2b or Ipilimumab in Resected High-Risk MelanomaKenneth F Grossmann, Megan Othus, Sapna P Patel, et al.Journal of the National Comprehensive Cancer Network : JNCCN|June 14, 2014
Dermatofibrosarcoma protuberans, version 1.2014Christopher K Bichakjian, Thomas Olencki, Murad Alam, et al.The Lancet. Oncology|May 17, 2021
Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trialAlexander J Stratigos, Aleksandar Sekulic, Ketty Peris, et al.The Lancet. Oncology|June 28, 2015
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trialAntoni Ribas, Igor Puzanov, Reinhard Dummer, et al.The New England Journal of Medicine|June 5, 2018
PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell CarcinomaMichael R Migden, Danny Rischin, Chrysalyne D Schmults, et al.Pageof 8